SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
Dated October 28, 2003
IMI International Medical Innovations Inc.
Commission File Number 1-31360
300-4211 Yonge Street
Toronto, Ontario M2P 2A9
CANADA
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F
Form 20-F X Form 40-F
--- ---
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ____
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ____
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant's "home country"), or under the rules of the home
country exchange on which the registrant's securities are traded, as long as the
report or other document is not a press release, is not required to be and has
not been distributed to the registrant's security holders, and, if discussing a
material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
1
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
--- ---
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ________
2
IMI International Medical Innovations Inc.
Form 6-K
On October 27, 2003, the Registrant publicly disseminated a press release
announcing that it will give a presentation at the MASS Opportunities
Biotechnology Investment Conference. The information contained in the press
release is incorporated herein by reference and filed as Exhibit 99 hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
IMI International Medical Innovations Inc.
By: /s/ Ronald G. Hosking
-------------------------------------------
Ronald G. Hosking
Vice President and Chief Financial Officer
Date: October 28, 2003
EXHIBIT INDEX
Exhibit
Number Description
-------- -----------
99 The Registrant's Press Release
Dated October 27, 2003
3
Exhibit 99
Press release
IMI TO PRESENT AT MASS OPPORTUNITIES
INVESTMENT CONFERENCE
Live webcast available
Multiple awareness-raising initiatives underway
TORONTO (October 27, 2003) - Predictive medicine company IMI International
Medical Innovations Inc. (TSX:IMI, Amex:IME) will offer a live webcast of its
presentation today at MASS Opportunities, the annual investment conference
hosted by the Massachusetts Biotech Council.
IMI President and CEO Dr. Brent Norton will give the presentation to the
investment audience in Boston at 11:50 a.m. ET today. The live webcast can be
heard through the IMI web site at www.imimedical.com. An archived version of the
presentation will be available for 30 days through IMI's Investor page.
"Today's presentation is one of several initiatives underway to expand awareness
of IMI into the U.S.," said Dr. Brent Norton. "Now that IMI stock is listed on
the American Stock Exchange in addition to The Toronto Stock Exchange, we are
substantially broadening our efforts to reach as many potential investors as
possible and build an understanding among them of IMI's novel approach to
predictive medicine."
Also this week, our Canadian marketing partner McNeil Consumer Healthcare is
exhibiting at the Canadian Cardiovascular Congress in Toronto, building further
awareness among Canadian cardiologists of IMI's non-invasive skin test for
coronary artery disease.
4
A new research report on IMI published this month by U.S.-based analysts for
Independent Equity Research Corp. (eResearch) is currently featured on the
Investrend web site (www.investrend.com) and is being distributed through the
Investrend network. IMI has also begun a broad distribution program for its news
releases throughout North America through the MacReport.net, a leading web
resource for investors.
About IMI
IMI is a world leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening diseases,
particularly cardiovascular disease and cancer. The company's lead product is a
non-invasive skin test for coronary artery disease. IMI is also developing a
suite of screening tests for cancer, including ColorectAlert(TM) for colorectal
cancer, LungAlert(TM) for lung cancer, and a new test for early-stage breast
cancer. For further information, please visit the company's web site at
www.imimedical.com.
This release contains forward-looking statements that reflect the company's
current expectation regarding future events. The forward-looking statements
involve risk and uncertainties. Actual events could differ materially from those
projected herein and depend on a number of factors including, but not limited
to, changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process, establishment
of corporate alliances and other risks detailed from time to time in the
company's quarterly, annual and other public filings.
- 30 -
For more information contact:
Andrew Weir
Director, Communications
(416) 222-3449
aweir@imimedical.com
5